0.96
price down icon0.41%   -0.004
after-market 시간 외 거래: .90 -0.06 -6.25%
loading
전일 마감가:
$0.964
열려 있는:
$1.01
하루 거래량:
12.49M
Relative Volume:
2.82
시가총액:
$8.34M
수익:
-
순이익/손실:
$-16.42M
주가수익비율:
-0.0412
EPS:
-23.3189
순현금흐름:
$-6.75M
1주 성능:
-2.61%
1개월 성능:
+6.67%
6개월 성능:
-65.59%
1년 성능:
+0.00%
1일 변동 폭
Value
$0.8502
$1.07
1주일 범위
Value
$0.8502
$1.09
52주 변동 폭
Value
$0.575
$23.13

Silexion Therapeutics Corp Stock (SLXN) Company Profile

Name
명칭
Silexion Therapeutics Corp
Name
전화
972-8-6286005
Name
주소
12 ABBA HILLEL ROAD, RAMAT GAN
Name
직원
14
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
SLXN's Discussions on Twitter

SLXN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SLXN
Silexion Therapeutics Corp
0.96 8.57M 0 -16.42M -6.75M -23.32
Biotechnology icon
ONC
Beone Medicines Ltd Adr
246.68 25.81B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.09 111.46B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 40.37M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.39 64.44B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
77.49 6.19B 0 -153.72M -103.81M -2.00

Silexion Therapeutics Corp 주식(SLXN)의 최신 뉴스

pulisher
09:54 AM

Silexion reports breakthrough in KRAS-driven cancer therapy By Investing.com - Investing.com Nigeria

09:54 AM
pulisher
09:45 AM

Silexion reports breakthrough in KRAS-driven cancer therapy - Investing.com Australia

09:45 AM
pulisher
09:14 AM

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers - The Manila Times

09:14 AM
pulisher
09:09 AM

Silexion Therapeutics Announces Groundbreaking Preclinical - GlobeNewswire

09:09 AM
pulisher
09:05 AM

Revolutionary Cancer Drug Shows 90% Inhibition Rate Against Pancreatic, Lung, and Colorectal Cancers in New Study - Stock Titan

09:05 AM
pulisher
May 26, 2025

Reviewing Silexion Therapeutics (NASDAQ:SLXN) & BioNTech (NASDAQ:BNTX) - Defense World

May 26, 2025
pulisher
May 23, 2025

Silexion Therapeutics Receives Nasdaq Delisting Notice - TipRanks

May 23, 2025
pulisher
May 22, 2025

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment - TradingView

May 22, 2025
pulisher
May 21, 2025

Silexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant Cancers - Nasdaq

May 21, 2025
pulisher
May 21, 2025

Silexion Therapeutics Completes Key Preclinical Studies Exploring Sil204's Potential Impact on Colorectal and Lung Cancer - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Silexion Completes Key Preclinical Studies for SIL204 - TipRanks

May 21, 2025
pulisher
May 21, 2025

Silexion Therapeutics Completes Key Preclinical Studies - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Major Cancer Treatment Advance: Silexion's RNAi Drug Shows Promise Against 3 Deadly Cancers in $30B Market - Stock Titan

May 21, 2025
pulisher
May 13, 2025

Form 424B3 Silexion Therapeutics - StreetInsider

May 13, 2025
pulisher
May 13, 2025

Silexion Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Silexion Therapeutics Reports Q1 2025 Financial Results and Key Developments in RNAi Cancer Therapy - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 13, 2025
pulisher
May 02, 2025

SLXNSilexion Therapeutics Corp Latest Stock News & Market Updates - Stock Titan

May 02, 2025
pulisher
Apr 25, 2025

Is Silexion Therapeutics Corp (SLXN) positioned for future growth? - Sete News

Apr 25, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Partners with Catalent to Advance Revolutionary KRAS-Targeting Cancer Therapy - citybuzz -

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics partners with Catalent for cancer drug development By Investing.com - Investing.com South Africa

Apr 23, 2025
pulisher
Apr 23, 2025

SLXN’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Partners With Catalent To Advance SIL204 SiRNA Therapy For KRAS-Driven Cancers - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Partners with Catalent for SIL204 Development - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics partners with Catalent for cancer drug development - Investing.com Australia

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics enters collaboration with Catalent - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Announces Collaboration with Global - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent - Stock Titan

Apr 23, 2025
pulisher
Apr 05, 2025

Titan Pharmaceuticals (NASDAQ:TTNP) and Silexion Therapeutics (NASDAQ:SLXN) Head to Head Review - Defense World

Apr 05, 2025
pulisher
Mar 31, 2025

Silexion plans dual-route strategy for SIL-204 for KRAS-driven pancreatic cancer - BioWorld MedTech

Mar 31, 2025
pulisher
Mar 29, 2025

Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion - TipRanks

Mar 29, 2025
pulisher
Mar 28, 2025

Silexion advances dual-route strategy for KRAS cancer therapy By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - markets.businessinsider.com

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Unveils Innovative Expanded - GlobeNewswire

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics announces expanded development plan for SIL204 - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Expands SIL204 Development Plan - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion advances dual-route strategy for KRAS cancer therapy - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204 - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Game-Changing Cancer Treatment: Silexion's New Dual-Action Drug Targets Both Primary Tumors and Metastases - Stock Titan

Mar 28, 2025
pulisher
Mar 23, 2025

Maxim Group Cuts Silexion Therapeutics (NASDAQ:SLXN) Price Target to $5.00 - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics price target lowered to $5 from $9 at Maxim - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion announces completion of expanded development plan for SIL204 - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 Conference - Nasdaq

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - GlobeNewswire

Mar 21, 2025
pulisher
Mar 21, 2025

Revolutionary KRAS Cancer Treatment: Silexion Expands Development Strategy for SIL204 - StockTitan

Mar 21, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Corp. Reports 2024 Financial Results and Progress on SIL204 for KRAS-Driven Cancers - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Corp SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 17, 2025

Revolutionary Cancer Drug SIL204 Tackles Both Primary Tumors and Metastasis with 80% Success Rate - StockTitan

Mar 17, 2025

Silexion Therapeutics Corp (SLXN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.06
price up icon 0.95%
$31.31
price up icon 3.40%
$580.95
price up icon 0.82%
$292.90
price up icon 2.57%
$4.64
price up icon 6.67%
$77.49
price up icon 4.82%
자본화:     |  볼륨(24시간):